Neuraptive
Neuraptive Therapeutics, Inc. is a biotechnology company focused on developing innovative treatments for peripheral nerve injuries. Their lead product, NTX-001, is a drug device combination designed to enhance nerve repair by preventing Wallerian degeneration, thereby restoring electrical signaling across severed peripheral nerves during surgery. The Company ran a Phase II study that demonstrated statistically significant improvements in patients in function, nerve recovery and pain. NTX-001 has Orphan Drug Designation and Breakthrough Therapy Designation. Neuraptive is preparing to initiate a registrational, double-blind, placebo-controlled Phase III program for NTX-001 in early 2025.
Latest news from Neuraptive
September 19, 2024
Neuraptive Therapeutics Announces Presentation of Phase 2 Topline Interim Results for NTX-001 at the 2024 American Society for Surgery of the Hand (ASSH) Annual Meeting
September 11, 2024
Neuraptive Therapeutics Receives FDA Breakthrough Therapy Designation for NTX-001 and Provides Update on the Advancements of NTX-001 for the Treatment of Peripheral Nerve Injury Requiring Repair
Feb 22, 2024
Neuraptive Therapeutics, Inc. Announces Positive 24-Week Data for NTX-001 in the Phase 2 NEUROFUSE Study, Reinforcing Previously Announced Proof of Concept 12-Week Data
Jan 15, 2024
Neuraptive Therapeutics Inc. Receives Orphan Drug Designation for its Lead Development Asset
Jan 8, 2024
